ArticleJournal of thoracic disease2025
Wuhu decoction regulates ROS/AMPK/mTOR pathway-mediated dendritic cells autophagy and pyroptosis for the treatment of respiratory syncytial virus-induced asthma.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Respiratory syncytial virus (RSV) infection is a major trigger of asthma, especially in children, and is associated with oxidative stress and inflammation. Emerging evidence suggests that dendritic cell (DC) pyroptosis and impaired autophagy contribute to asthma pathogenesis. Wuhu decoction (WHD), a traditional Chinese herbal formula, has shown clinical potential in asthma management, but its mechanisms remain unclear. This study aimed to investigate the mechanism by which WHD regulates DCs autophagy and pyroptosis to prevent and treat RSV-induced asthma, as well as its regulatory effect on the reactive oxygen species (ROS)/AMPK/mTOR pathway. Methods: One hundred specific pathogen-free-grade male Bagg Albino/c mice were induced with asthma by inhalation of RSV complexed with ovalbumin (OVA). After successful modeling, the mice were designated into control, model group, WHD low-dose, WHD medium-dose, WHD high-dose, dexamethasone, rapamycin, 3-MA, MCC950 group, and these treatments lasted for 2 weeks. Respiratory responsiveness of mice was measured by plethysmography. Lung tissue pathology changes, goblet cell mucin secretion, and airway collagen deposition were assessed with histology. Flow cytometry detected ROS activity in lung tissue. Transmission electron microscopy examined lung autophagosomes. Western blot determined expression of airway remodeling-related proteins α-smooth muscle actin (α-SMA) and transforming growth factor-β (TGF-β), autophagy-, pyroptosis-, pathway-related proteins in lung tissue DCs. Results: Comparing to controls, asthmatic mice exhibited increased airway responsiveness, peri-bronchial inflammatory cell infiltration, goblet cell hyperplasia, and widespread airway collagen deposition. α-SMA and TGF-β proteins in lung tissue were significantly elevated, and ROS activity in lung tissues was enhanced. DCs autophagy level in lungs was increased and DCs pyroptosis was increased, while p-AMPK/AMPK protein in lung tissue DCs was decreased, and p-mTOR/mTOR protein level was increased in asthmatic mice comparing to controls. Comparing to model mice, medium and high dose of WHD, rapamycin and MCC950 significantly reduced airway responsiveness in asthmatic mice, alleviated airway inflammation, epithelial cell proliferation, and widespread deposition of TGF-β and α-SMA proteins in lung tissues, as well as reduced ROS activity. Furthermore, these interventions further enhanced DCs autophagy, inhibited DCs pyroptosis, promoted p-AMPK expression, and inhibited p-mTOR expression in DCs of lung tissues. Conclusions: WHD may activate DCs autophagy through the ROS/AMPK/mTOR axis, inhibit NLRP3 inflammasome-induced cell pyroptosis, and thus prevent and treat RSV-induced asthma in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.